Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part of the aging process, including immunosenescence, is explained by an imbalance between inflammatory and anti-inflammatory networks, wich results in the low grade chronic pro-inflammatory status termed inflammaging. It can contribute to a number of age-related chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis). Prevention or delay in onset of chronic diseases can potentially benefit a large segment of the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade inflammation through improvement of the gut barrier function and gut microbiota composition in elderly people with low-grade inflammation.
Full description
Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part of the aging process, including immunosenescence, is explained by an imbalance between inflammatory and anti-inflammatory networks, wich results in the low grade chronic pro-inflammatory status termed inflammaging. It can contribute to a number of age-related chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis). Prevention or delay in onset of chronic diseases can potentially benefit a large segment of the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade inflammation through improvement of the gut barrier function and gut microbiota composition in elderly people with low-grade inflammation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Men >65 years of age.
- Body mass index: 22-34,9 kg/m²
- non-smokers
Intervention trial:
- hsCRP > 1 mg/L (Screening blood test)
- normal blood count (Screening blood test)
- normal ALAT, ASAT and serum creatinine levels (Screening blood test)
Exclusion criteria
- any major non-organic disease, including malign diseases (haematological, inflammatory, metabolic,)
- any major organ disease, including neoplastic diseases.
- intake of antibiotics within the last 6 weeks
- chronic therapy with analgetics (incl. acetylsalicylic acid)
- chronic therapy with proton pump inhibitors
- regular intake of probiotic bacteria products within the last 3 weeks
- chronic anti-inflammatory therapy with NSARs or previous therapy within the last 20 days
- subjects with expected non-compliance to protocol guidelines
- subjects that participate in other trials
Trial design
Primary purpose
Allocation
Interventional model
Masking
48 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal